Moxifloxacin + meronam
PreclinicalSmall molecule
Moxifloxacin + meronam is one of 6 small molecule programs targeting Empyema. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Empyema
#DrugCompanyPhaseTrials
1Betadine
BBecton, Dickinson and Company
Approved
Activase
RochePhase 3
Urokinase
Mmedac GmbH
Phase 3
Tpa
UUniversity of Florida
Phase 3
Dnase
TThe Hospital for Sick Children
Phase 3
Moxifloxacin + meronam
FFayoum University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moxifloxacin + meronam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFayoum University